Preliminary results of the ADARNAT pilot phase suggest that axillary radiotherapy (ART) without lymphadenectomy might safely replace axillary lymphadenectomy (ALND) in patients with limited node disease. Amparo Garcia-Tejedor (Hospital Universitari de Bellvitge, Gynecology, Hospitalet de Llobregat, Spain) presented results from the pilot phase of ADARNAT trial, an open-label, randomised, phase 3 multicentre trial across 23 Spanish hospitals. 272 patients with breast cancer (cT1–T4b, and cN0–cN1) treated with neoadjuvant therapy and 1–2 positive sentinel lymph nodes at surgery were randomly assigned to receive ART or ALND.
The Lancet Oncology published a clinical update in Oncology on 02 Apr 2026. The item focuses on European Breast Cancer Conference 2026. Open the detail page to review the full original feed content.